Skip to main content

MoneyWorks4Me

Syngene International informs about updates

15 Nov 2022 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, Syngene International has informed that the US Food and Drug Administration (FDA) has conducted its pre-approval inspection of the Biologics facility at Bangalore from November 07, 2022 till November 15, 2022. The inspection was completed successfully without 483 observations. The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sagility 44.67
Prime Focus 279.25
Indegene 614.25
Syngene Internatl. 436.95
Knowledge RealtyTrt. 112.00
View more..